
Lundbeck is still interested in acquisitions, despite the fact that the firm and its partner Otsuka Pharmaceuticals released positive phase III data for its candidate brexpiprazol on Monday. The target indication is agitation in Alzheimer’s patients, which is often demonstrated through angry outbursts.
”We know that we need to address Lundbeck’s future growth, in terms of the next five to ten years” CEO Deborah Dunsire tells Danish financial daily Børsen.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app